Skyepharma’s pre-close trading update highlights the early recognition in 2015 of a €10m flutiform® sales milestone (previously expected in 2016) and cash significantly ahead of estimates, reflecting strong business performance and an element of later capital expenditure payments. In addition, as we recently commented, we are confident that continued strong sales of EXPAREL® by Pacira will trigger an $8m milestone to Skyepharma in 2016. Against a backdrop of solid progress in 2015, we continue to believe that Skyepharma has a highly attractive offering and recommend the stock as a core holding in the sector.
